ArticleResearch (Washington, D.C.)2025
Isovalerylspiramycin I Reprograms the Immunosuppressive and Temozolomide-Resistant Microenvironment by Inhibiting the Frizzled-5/Wnt/β-Catenin Pathway in Glioblastoma.
Article in Research (Washington, D.C.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Targeting frizzled receptors (FZDs) for anti-tumor therapy: From orthosteric to allosteric inhibition.Acta pharmaceutica Sinica. B · 2026Review
- Bufalin targets E2F2 to transcriptionally inhibit LINC01410 and suppress Wnt/β-catenin signaling in esophageal squamous cell carcinoma.NPJ precision oncology · 2026Article
- Frizzled-4 promotes bone formation in chickens via activation of the canonical Wnt signaling pathway.Poultry science · 2026Article
- A New Fluorine-18-Fluoroethyltyrosine Positron-Emission-Tomography/Magnetic-Resonance-Based Tumor Resection Plan Improved the Prognosis of Glioblastoma Patients. A Multicenter Validated Study.Research (Washington, D.C.) · 2026Article
- 20(S)-protopanaxadiol enhances temozolomide responsiveness in MGMT-expressing glioblastoma: Wnt/β-catenin attenuation and MGMT downregulation.Frontiers in medicine · 2026Article
- Post-Translational Modifications in Cancer-Associated CD8⁺ T-Cell Exhaustion: Mechanisms and Therapeutic Opportunities.International journal of biological sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM), the most prevalent and lethal primary brain malignancy in adults, currently lacks treatment effective options. Repurposing existing pharmaceutical agents as novel therapeutic modalities represents a viable strategy for efficiently utilizing resources. Here, we demonstrated that Isovalerylspiramycin I (ISP-I), the active component of a novel macrolide antibiotic, exerts a synergistic effect with temozolomide (TMZ) to enhance anti-GBM efficacy. ISP-I potently induced cytotoxicity and apoptosis through the induction of DNA double-strand breaks. The synergistic activity (combination index < 1) was confirmed for ISP-I in combination with TMZ against GBM. Additionally, ISP-I was found to induce immunogenic cell death, as evidenced by increased adenosine triphosphate release and calreticulin exposure. In murine models, ISP-I increased tumor-infiltrating CD8
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.